Recurrent B-cell neoplasms after Rituximab therapy: An immunophenotypic and genotypic study

Leukemia and Lymphoma

Volumn 43, Issue 12, 2002, Pages 2335-2341

  Chu, Peiguo G ^a   Chen, Yuan Yuan ^a   Molina, Arturo ^a   Arber, Daniel A ^a   Weiss, Lawrence M ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

B cell neoplasms; CD20; Flow cytometry; Immunohistochemistry; Polymerase chain reaction; Rituximab

Indexed keywords

BETA GLOBIN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD45 ANTIGEN; CD79A ANTIGEN; CELL DNA; CELL MARKER; EOSIN; HEMATOXYLIN; IMMUNOGLOBULIN HEAVY CHAIN; PARAFFIN; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; CANCER RECURRENCE; CONTROLLED STUDY; DNA EXTRACTION; FLOW CYTOMETRY; GENE REARRANGEMENT; GENETIC ANALYSIS; GENETIC VARIABILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT DISEASE; TISSUE SECTION; TUMOR CELL; UNITED STATES; CLASSIFICATION; FOLLOW UP; GENOTYPE; PATHOLOGY; TREATMENT FAILURE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FOLLOW-UP STUDIES; GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; GENE REARRANGEMENT, B-LYMPHOCYTE, LIGHT CHAIN; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; RECURRENCE; TREATMENT FAILURE;

EID: 0036891188     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819021000040044     Document Type: Article

References (20)

1. Golay, J.T., Clark, E.A. and Beverley, P.C. (1985) "The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle", Journal of Immunology 135, 3795-3801.
2. Tedder, T.F., Forsgren, A., Boyd, A.W., Nadler, L.M. and Schlossman, S.F. (1986) "Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes", European Journal of Immunology 16, 881-887.
3. Chang, K.L., Arber, D.A. and Weiss, L.M. (1996) "CD20: A review", Applied Immunohistochemistry 4, 1-15.
4. Sacchi, S., Federico, M., Dastoli, G., Fiorani, C., Vinci, G., Clo, V. and Casolari, B. (2001) "Treatment of B-cell non-Hodgkin's lymphoma with anti CD20 monclonal antibody Rituximab", Critical Review of Oncology/Hematology 37, 13-25.
5. Reff, M.E., Carner, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., Newman, R.A., Hanna, N. and Anderson, D.R. (1994) "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20", Blood 83, 435-445.
6. Maloney, D.G. (2001) "Preclinical and phase I and II trials of Rituximab", Seminar in Oncology 26, 74-78.
7. McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Brucklet, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. and Dallaire, B.K. (1998) "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program", Journal of Clinical Oncology 16, 2825-2833.
8. Czuczman, M.S., Grillo-Lopez, A.J., White, C.A., Saleh, M., Gordon, L., LoBuglio, A.F., Jonas, C., Klippen Stein, D., Dallaire, B. and Varns, C. (1999) "Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy", Journal of Clinical Oncology 17, 268-276.
9. Davis, T.A., Czerwinski, D.K. and Levy, R. (1999) "Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression", Clinical Cancer Research 5, 611-615.
10. Kinoshita, T., Nagai, H., Murate, T. and Saito, H. (1998) "CD20-negative relapse in B-cell lymphoma after treatment with Rituximab", Journal of Clinical Oncology 16, 3916.
11. Foran, J.M., Norton, A.J., Micallef, I.N., Taussig, D.C., Amess, J.A., Rohatiner, A.Z. and Lister, T.A. (2001) "Loss of CD20 expression following treatment with Rituximab (chimeric monoclonal anti-CD20): a retrospective cohort analysis", British Journal of Haematology 114, 881-883.
12. Schmitz, K., Brugger, W., Weiss, B., Kaiserling, E. and Kanz, L. (1999) "Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody Rituximab", British Journal of Haematology 106, 571-572.
13. Venugopal, P., Leslie, W.T., O'Brien, T. and Gregory, S.A. (1999) "CD20-negative relapse after (131)I-anti-CD20 therapy", Journal of Clinical Oncology 17, 3692-3693.
14. Khalidi, H.S., Chang, K.L., Medeiros, L.J., Brynes, R.K., Slovak, M.L., Murata-Collins, J.L. and Arber, D.A. (1999) "Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases", American Journal Clinical Pathology 111, 467-476.
15. Segal, G.H., Jorgensen, T., Masih, A.S. and Braylan, R.C. (1994) "Optimal primer selection for clonality assessment by polymerase chain reaction analysis: I. Low grade B-cell lymphoproliferative disorders of nonfollicular center cell type", Human Pathology 25, 1269-1275.
16. Gong, J.Z., Zheng, S., Chiarle, R., Wolf-Peeters, C., Palestro, G., Frizzera, G. and Inghirami, G. (1999) "Detection of immunoglobulin kappa light chain rearrangements by polymerase chain reaction. An improved method for detecting clonal B-cell lymphoproliferative disorders", American Journal of Pathology 155, 355-363.
17. Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., Janakiraman, N., Foon, K.A., Liles, T.M., Dallaire, B.K., Wey, K., Royston, I., Davis, T. and Levy, R. (1997) "IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma", Blood 90, 2188-2195.
18. Meeker, T., Lowder, J., Cleary, M.L., Stewart, S., Warnke, R., Sklar, J. and Levy, R. (1985) "Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies", New England Journal of Medicine 312, 1658-1665.
19. Vuist, W.M., Levy, R. and Maloney, D.G. (1994) "Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein", Blood 83, 899-906.
20. Abdel-Reheim, F.A., Edwards, E. and Arber, D.A. (1996) "Utility of a rapid polymerase chain reaction panel for the detection of molecular changes in B-cell lymphoma", Archives Pathology and Laboratory Medicine 120, 357-363.